Gary Richardson

Projects

Projects per year 2018 2020 2021 2022 2023 2027

• 2 Not started
• 17 Active
• 47 Finished

Projects per year

Search results

• Finished

  A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers

  Richardson, G. (Primary Chief Investigator (PCI))

  13/09/23 → 13/09/23

  Project: Research

• Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6- positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

  Richardson, G. (Primary Chief Investigator (PCI))

  4/07/23 → 3/07/25

  Project: Research

• Phase 1/2, Two-Part, Multi-center, Open-label, Dose Escalation and Dose Expansion First-In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB088C in Participants with Advanced or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  24/02/23 → 24/02/24

  Project: Research

• Phase 1/2, Multi-center, Open-label, Dose Escalation and Dose Expansion First -In-Human Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants with Advanced or Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI))

  24/02/23 → 24/02/25

  Project: Research

• There is also an updated standard indemnity where the study Name has been updated to A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 Conditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  7/12/22 → 7/12/24

  Project: Research

• Generation of a pre-clinical testing platform to enable selection of personalised drug treatments for patients with BRAF-mutant Colorectal cancer (CRC)

  Abud, H. (Primary Chief Investigator (PCI)), Engel, R. (Chief Investigator (CI)), McMurrick, P. (Chief Investigator (CI)), Shapiro, J. (Chief Investigator (CI)), Archer, S. (Chief Investigator (CI)) & Richardson, G. (Chief Investigator (CI))

  1/11/22 → 31/01/24

  Project: Research

• A multicenter, open-label, phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YH002 in combination with YH001 in subjects with advanced solid tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  17/03/22 → 31/12/24

  Project: Research

• Phase 1-2 study investigating, safety, tolerability, pharmacokinetics and preliminary antitumor activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in patients with advanced solid tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  9/03/22 → 31/12/24

  Project: Research

• A first-in-human Phase 1 study of NL-201 in patients with relapsed or refractory cancer.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  18/02/22 → 1/12/24

  Project: Research

• PICCOLO: A Phase 2, single arm study of Mirvetuximab Soravtansine in recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  11/02/22 → 31/12/24

  Project: Research

• A first in human Phase 1/2 open-label, multicentre, dose escalation and expansion study of PRS-344/S095012 in patients with solid tumors.

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  1/02/22 → 30/11/24

  Project: Research

• A multi-center, single-arm and open-label Phase Ib/II study exploring the safety/tolerability, pharmacokinetics and efficacy of GFH018 in combination with Toripalimab in the treatment of patients with advanced solid tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  8/12/21 → 31/12/24

  Project: Research

• Phase 1 b/2a study investigating ATX-101 in combination with platinum-based chemotherapy in platinum-sensitive, recurrent ovarian, fallopian tube and primary peritoneal cancer

  Richardson, G. (Primary Chief Investigator (PCI)) & Spence, A. (Project Manager)

  22/11/21 → 31/12/24

  Project: Research

• An ascending single and multiple dose study of the safety, tolerability, pharmacokinetics and anti-tumour activity of once-daily oral treatment with EO1001 in patients with advanced cancer.

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  20/11/21 → 31/12/24

  Project: Research

• A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  21/10/21 → 31/12/24

  Project: Research

• A Phase I, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients with Locally Advanced Unresectable/Metastatic Solid Tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  27/09/21 → 31/12/24

  Project: Research

• A Phase 1 First in Human, Multicentre, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of CCX559 in Subjects with Solid Tumors [CL001_559]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  1/09/21 → 31/12/24

  Project: Research

• A Phase 1, First-in-Human, Open-Label, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-061 Tablet in Subjects with Advanaced Tumours

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  14/07/21 → 31/12/24

  Project: Research

• A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma [ZN-c3-004]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  18/05/21 → 31/12/24

  Project: Research

• A randomised, multicentre, double-blind, placebo-controlled, phase III study of first line Carboplatin and Paclitaxel in combination with Durvalumab, followed by maintenance durvalumab with or without Olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer [DUO-E]

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  14/04/21 → 31/12/24

  Project: Research

• A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of KF-0210 in Patients with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Hoon, L. L. (Project Manager)

  11/03/21 → 31/12/24

  Project: Research

• A First-in-Human (FIH), Open-Label, Phase I Dose Escalation and Expansion Study of ADG126, ADG126 in Combination with Toripalimab, and ADG126 in Combination with ADG106 in Patients with Advanced/Metastatic Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  11/03/21 → 31/12/24

  Project: Research

• A randomised, open-label phase 3 study of combination amivantamab and carboplatin-pemetrexed therapy, compared with carboplatin-pemetrexed, in patients with EGFR Exon 20ins mutated locally advanced or metastatic non-small cell lung cancer (PAPILLON)

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  1/03/21 → 31/12/24

  Project: Research

• A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [MARIPOSA].

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  26/02/21 → 31/12/23

  Project: Research

• A phase 1/2, open-label study to evaluate the safety, tolerability, pharmacokinetics and efficacy of D-1553 in subjects with advanced or metastatic solid tumors with KRasG12C mutation

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  20/01/21 → 31/12/24

  Project: Research

• Treatment for a poor prognosis subset of estrogen receptor breast cancers.

  Mitchell, C. (Primary Chief Investigator (PCI)), McLean, C. (Chief Investigator (CI)), Loi, S. (Associate Investigator (AI)) & Richardson, G. (Associate Investigator (AI))

  1/01/21 → 31/12/23

  Project: Research

• A phase 1, first in human, multicenter, open-label, study of GQ1001, a HER2 targeted antibody-drug conjugate administered intravenously in adult patients with HER2 - positive advanced solid tumors [GQCT001/GQ1001X2101]

  Richardson, G. (Primary Chief Investigator (PCI))

  1/12/20 → 31/12/24

  Project: Research

• MIRASOL: A randomised, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

  Richardson, G. (Primary Chief Investigator (PCI)) & Lai, L. H. (Project Manager)

  30/11/20 → 31/12/24

  Project: Research

• A PHASE 1b STUDY OF ZN-c3 IN COMBINATION WITH CHEMOTHERAPY OR BEVACIZUMAB IN SUBJECTS WITH OVARIAN, PERITONEAL, OR FALLOPIAN TUBE CANCER

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  22/10/20 → 31/12/22

  Project: Research

• An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell Lung Cancer (IMPrinter)

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  14/10/20 → 31/12/24

  Project: Research

• A phase 1, open-label, dose escalation study of ADG116 in patients with advanced/metastatic solid tumors [ADG116-1003].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  24/09/20 → 31/12/23

  Project: Research

• A phase 1, open label, multi-center, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of CN1 in patients with advanced solid tumors or B-cell lymphoma [CN1-101].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  27/08/20 → 31/12/22

  Project: Research

• An open label Phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  1/07/20 → 31/12/22

  Project: Research

• A phase 1a/1b, open-label, dose-escalation and dose-expansion study of the anti-CTLA-4 monoclonal antibody CS1002 as monotherapy and in combination with anti-PD-1 monoclonal antibody CS1003 in subjects with advanced solid tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  19/06/20 → 31/12/23

  Project: Research

• An open label Phase 1B dose finding study of BI 836880 in combination with BI 754091 to characterise safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous non-small cell lung cancer and in other solid tumours.

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  3/06/20 → 31/12/22

  Project: Research

• Open-label Phase 2 study of Ladiratuzumab Vedotin (LV) for unresectable locally advanced or metastatic solid tumors [SGNLVA-005]

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  13/05/20 → 31/12/24

  Project: Research

• A Phase I, Multi-center, Open-label, Dose Escalataion Study of CS3005 in Subjects with Advanced Solid Tumors

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  5/03/20 → 31/12/22

  Project: Research

• A phase 1/2, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumors, with expansion to second line cervical cancer [C-700-001].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  10/09/19 → 31/12/24

  Project: Research

• A phase 1, open-label, multi-center, non randomised, dose escalation study to evaluate the safety, tolerability and pharmacokinetic profile of XNW7201 in subjects with advanced solid tumors [XNW7201-1-02).

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  22/07/19 → 31/12/24

  Project: Research

• A phase 1a/1b multicenter, open-label, dose escalation, dose expansion study evaluating the safety, pharmacokinetics and activity of GDC-9545 alone or in combination with palbociclib and/or LHRH agonist in patients with locally advanced or metastatic estrogen receptor-positive breast cancer [GO39932].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  24/05/19 → 31/12/24

  Project: Research

• A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with gastrointestinal malignancies [AB928CSP0003].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  28/02/19 → 31/12/24

  Project: Research

• A phase 1/1b study to evaluate the safety and tolerability of immunotherapy combinations in participants with breast or gynaecologic malignancies [AB928CSP0002].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  28/02/19 → 31/12/24

  Project: Research

• A phase 1 study to evaluate the safety and tolerability of immunotherapy combinations in participants with advanced malignancies [AB928CSP0005].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  28/02/19 → 31/12/24

  Project: Research

• Combating adaptive resistance to tageted therapy in triple-negative breast cancer

  Nguyen, L. (Primary Chief Investigator (PCI)), Swarbrick, A. (Associate Investigator (AI)), Richardson, G. (Associate Investigator (AI)), Loi, S. (Associate Investigator (AI)) & Daly, R. (Associate Investigator (AI))

  15/02/19 → 14/02/23

  Project: Research

• A phase 1a/1b study of FPT155 in patients with advanced solid tumours [FPT155-001].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  10/12/18 → 31/12/23

  Project: Research

• A phase 1b/2 study of BMS-813160 in combination with chemotherapy or Nivolumab in patients with advanced solid tumors [CV202-103].

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  10/12/18 → 31/12/24

  Project: Research

• A randomized, open-label, multicenter, phase 3 study to evaluate the efficacy and safety of Avelumab in combination with chemotherapy followed by maintenance therapy of Avelumab in combination with the poly (adenosine diphosphate [Adp] - ribose) polymerase (Parp) inhibitor talazoparib in patients with previously untreated advanced ovarian cancer (JAVELIN OVARIAN PARP 100) [B9991030]

  Richardson, G. (Primary Chief Investigator (PCI)) & Baker, E. (Project Manager)

  4/12/18 → 31/12/20

  Project: Research